Opinion on R&D in Europe

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Liberate: a Two Way bet on enhanced programming

Liberate 1.2 includes enhanced programming software from Two Way TV, allowing TV operators to link interactive services directly to scheduled programs. Since enhanced programming is likely to be a major driver of iTV usage, middleware vendors must either develop proprietary solutions in this area, or rapidly integrate third party technologies to avoid delays to roll-out.

Published By Datamonitor
24 Apr 2002
CommentWire
CommentWire

L'Oreal: looking pretty

Despite a weaker than expected Q4, due to the euro changeover and September 11, L'Oreal's global reach and product portfolio has brought good overall 2001 results. Its acquisition of BioMedic, meanwhile, will help sustain strong growth in the active cosmetics division through 2002. This should make L'Oreal a leading player in the emerging skincare cosmeceutical market.

Published By Datamonitor
24 Jan 2002
CommentWire
CommentWire

KPN Mobile: the second coming isn't pre-paid

While i-mode is being hailed as the 'second coming' for European mobile data services, various obstacles may deter its uptake. In particular, KPN is not rolling out a pay-as-you-go service - instead, it requires a subscription. This is likely to deter young users, whose viral marketing has been one of the factors driving the service's Japanese success.

Published By Datamonitor
17 Apr 2002
CommentWire
CommentWire

John Lewis: merging dotcoms

Given that the main reason John Lewis bought Buy.com was to gain its technology, the move is hardly unexpected. It should strengthen John Lewis's online brand and increase Johnlewis.com's site traffic - both sensible objectives. However, Johnlewis.com's limited range of technology products will drive away some of Buy.com's customers.

Published By Datamonitor
22 Jan 2002
Expert View
Expert View

Janssen and Eli Lilly come to blows with their antipsychotics

The war between Janssen's Risperdal and Eli Lilly's Zyprexa has been raging for several years. With the recent FDA approval of Risperdal for delaying relapse in the long-term treatment of schizophrenia, the battle could hot up. So with Lilly also having to beat off generic competition, will Zyprexa become another Prozac?

Published By Datamonitor
12 Apr 2002
Expert View
Expert View

Ironing out the Glivec-glitch

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, the National Institute of Clinical Excellence has decided to limit its use in chronic myeloid leukemia patients to the accelerated phase only, due to the lack of cost-effective data. Datamonitor's Oliver Luft investigates Glivec's costly delay and asks what can be done to prevent future hold-ups.

Published By Datamonitor
24 May 2002
CommentWire
CommentWire

ICI: a sporting chance

Published By Datamonitor
08 Oct 2001
CommentWire
CommentWire

Hyundai: diesel va va voom

Published By Datamonitor
21 Sep 2001
Expert View
Expert View

Hyaluronic acid: osteoarthritis patients feel the need

New research finds that in certain European countries and Japan in particular, hyaluronic acid therapy is quite popular among knee osteoarthritis patients who are looking to reduce pain, improve joint mobility, and potentially delay knee surgery. However, a lack of evidence supporting the therapy's effectiveness is holding it back in the US and Europe.

Published By Datamonitor
14 Jun 2002
CommentWire
CommentWire

Hutchison 3G: rushing to market

While H3G seems to be the best-placed new entrant 3G mobile operators in Europe, it's hardly in an enviable position. H3G plans a limited roll-out this year, but its handsets will not switch properly between 2G and 3G networks. Given consumer antipathy towards new mobile technologies that don't work, H3G might be best advised to delay its launch.

Published By Datamonitor
30 Jul 2002

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.